Form 4: CytoDyn Director Granted 574,385 Stock Options

CytoDyn Inc. director Tanya Durkee Urbach received a grant of 574,385 non-qualified stock options with an exercise price of $0.28, vesting monthly through March 2027.

Summary

• Tanya Durkee Urbach, a Director of CytoDyn Inc. (CYDY), was granted 574,385 non-qualified stock options.
• The options have an exercise price of $0.28 per share.
• The grant was approved by the Company's Compensation Committee on March 20, 2026, as an annual grant for fiscal year 2026.
• The award is consistent with past practice in recent years and utilizes shares reserved under the Issuer's 2012 Equity Incentive Plan, as amended.
• The stock options will vest in 12 approximately equal monthly installments, beginning April 2026 and concluding in March 2027.
• The expiration date for these options is March 20, 2036.
• Following this transaction, Tanya Durkee Urbach beneficially owns 574,385 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine director compensation that aligns interests without indicating significant operational changes or financial distress.

Positives

• The grant aligns the director's financial interests with the long-term performance of CytoDyn Inc. and its shareholders.
• The award is part of a consistent annual compensation practice for directors, indicating stable corporate governance regarding executive and director incentives.

Negatives

• The issuance of new stock options, upon exercise, could lead to a minor dilution of existing shareholder equity.

Future Outlook

The vesting schedule for the stock options, extending through March 2027, implies a continued commitment of the director to the company's performance over the next year.

Industry Context

StockSavvy.ai notes that this grant is a standard form of non-cash compensation for directors in the biotechnology sector, aiming to align their interests with the company's long-term performance and shareholder value.

Comparison to Industry Standards

• StockSavvy.ai notes that annual equity grants to non-executive directors are a common practice in the biotechnology industry, aligning director incentives with long-term shareholder value.
• Similar practices are observed at companies like Amgen (AMGN) and Gilead Sciences (GILD), where directors often receive a mix of cash and equity compensation, with equity components typically vesting over several years to encourage sustained performance.

Stakeholder Impact

• Shareholders: Potential minor dilution upon exercise of options, but also benefit from aligned director incentives.
• Employees: No direct impact mentioned in this filing.

Next Steps

• The stock options will vest in 12 approximately equal monthly installments from April 2026 through March 2027.

Key Dates

Keywords

CytoDyn, CYDY, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Non-qualified Stock Option